101 related articles for article (PubMed ID: 25932543)
1. 18F-FDG-avid plantar nodules on true whole-body 18F-FDG PET/CT in cancer patients.
Muzaffar R; Raslan O; Osman MM
Nucl Med Commun; 2015 Sep; 36(9):881-6. PubMed ID: 25932543
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact of "true whole-body" (18)F-FDG PET/CT: lesion frequency and added benefit in distal lower extremities.
Kawata S; Imaizumi M; Kako Y; Oku N
Ann Nucl Med; 2014 May; 28(4):322-8. PubMed ID: 24488705
[TBL] [Abstract][Full Text] [Related]
3. Increased F-18 FDG uptake on positron emission tomography/computed tomography imaging caused by plantar fibromatosis.
Scheler J; Rehani B; Percy T; Pelstring R; Bharija A; Ames D; Mantil J
Clin Nucl Med; 2008 Apr; 33(4):280-1. PubMed ID: 18356670
[TBL] [Abstract][Full Text] [Related]
4. 18F-FDG PET/CT of patients with cancer: comparison of whole-body and limited whole-body technique.
Osman MM; Chaar BT; Muzaffar R; Oliver D; Reimers HJ; Walz B; Nguyen NC
AJR Am J Roentgenol; 2010 Dec; 195(6):1397-403. PubMed ID: 21098201
[TBL] [Abstract][Full Text] [Related]
5. PET/CT for the staging and follow-up of patients with malignancies.
Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
[TBL] [Abstract][Full Text] [Related]
6. Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study.
Klenk C; Gawande R; Uslu L; Khurana A; Qiu D; Quon A; Donig J; Rosenberg J; Luna-Fineman S; Moseley M; Daldrup-Link HE
Lancet Oncol; 2014 Mar; 15(3):275-85. PubMed ID: 24559803
[TBL] [Abstract][Full Text] [Related]
7. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
Metser U; Even-Sapir E
Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic performance of CT attenuation values of focal 18F-FDG avid breast lesions detected on whole-body PET-CT in postoperative breast cancer patients.
Plaza MJ; Collado-Mesa F; Bokhoor J; Alperin N; Yepes MM
Breast J; 2014; 20(3):235-42. PubMed ID: 24750508
[TBL] [Abstract][Full Text] [Related]
9. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
[TBL] [Abstract][Full Text] [Related]
10. Focal fluorine-18 fluorodeoxyglucose-avid lesions without computed tomography correlate at whole-body positron emission tomography-computed tomography in oncology patients: how often are they malignant?
Kumar R; Hawkins RA; Yeh BM; Wang ZJ
Nucl Med Commun; 2011 Sep; 32(9):802-7. PubMed ID: 21685821
[TBL] [Abstract][Full Text] [Related]
11. The impact of 18F-FDG PET/CT on assessment of nasopharyngeal carcinoma at diagnosis.
King AD; Ma BB; Yau YY; Zee B; Leung SF; Wong JK; Kam MK; Ahuja AT; Chan AT
Br J Radiol; 2008 Apr; 81(964):291-8. PubMed ID: 18344274
[TBL] [Abstract][Full Text] [Related]
12. Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT.
van Ufford HM; Kwee TC; Beek FJ; van Leeuwen MS; Takahara T; Fijnheer R; Nievelstein RA; de Klerk JM
AJR Am J Roentgenol; 2011 Mar; 196(3):662-9. PubMed ID: 21343511
[TBL] [Abstract][Full Text] [Related]
13. Clinical and therapeutic impact of 18F-FDG PET/CT whole-body acquisition including lower limbs in patients with malignant melanoma.
Querellou S; Keromnes N; Abgral R; Sassolas B; Le Roux PY; Cavarec MB; Le Duc-Pennec A; Couturier O; Salaun PY
Nucl Med Commun; 2010 Sep; 31(9):766-72. PubMed ID: 20585271
[TBL] [Abstract][Full Text] [Related]
14. Characterizing POEMS Syndrome with 18F-FDG PET/CT.
Pan Q; Li J; Li F; Zhou D; Zhu Z
J Nucl Med; 2015 Sep; 56(9):1334-7. PubMed ID: 26182964
[TBL] [Abstract][Full Text] [Related]
15. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
16. The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT.
Bogsrud TV; Karantanis D; Nathan MA; Mullan BP; Wiseman GA; Collins DA; Kasperbauer JL; Strome SE; Reading CC; Hay ID; Lowe VJ
Nucl Med Commun; 2007 May; 28(5):373-81. PubMed ID: 17414887
[TBL] [Abstract][Full Text] [Related]
17. Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results.
Ozkan E; Aras G; Kucuk NO
Clin Nucl Med; 2013 May; 38(5):326-31. PubMed ID: 23486319
[TBL] [Abstract][Full Text] [Related]
18. 18F-FDG PET and PET/CT in diagnosis and treatment monitoring of pyrexia of unknown origin due to tuberculosis with prominent hepatosplenic involvement.
Shejul Y; Chhajed PN; Basu S
J Nucl Med Technol; 2014 Sep; 42(3):235-7. PubMed ID: 24948823
[TBL] [Abstract][Full Text] [Related]
19. Utility of combined (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors.
Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Oral Oncol; 2009 Mar; 45(3):218-24. PubMed ID: 18804404
[TBL] [Abstract][Full Text] [Related]
20. The feasibility of 11C-methionine-PET in diagnosis of solitary lung nodules/masses when compared with 18F-FDG-PET.
Hsieh HJ; Lin SH; Lin KH; Lee CY; Chang CP; Wang SJ
Ann Nucl Med; 2008 Jul; 22(6):533-8. PubMed ID: 18670862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]